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Abstract
Chediak^Higashi syndrome (CHS) is an autosomal recessive disease characterized by the presence of abnormally large
cytoplasmic organelles in all body granule producing cells. The molecular mechanism for this disease is still unknown.
Functional disorders in membrane-related processes have been reported. Erythrocyte membranes from four CHS patients
and 15 relatives including obligatory heterozygous were studied to examine potential alterations in the lipid and fatty acid
profile of erythrocyte membranes associated with this syndrome. Plasma concentrations of cholesterol, triglycerides,
phospholipids, and apolipoproteins AI and B100, and the lipid components of very low-, intermediate-, low- and high-
density lipoproteins were also determined. CHS erythrocyte membranes were found to be enriched with lipids in relation to
protein and to show: (1) an increase in cholesterol and choline-containing phospholipids (sphingomyelin and
phosphatidylcholine) that predominate in the outer monolayer, which is higher than the increase in phosphatidylserine
and phosphatidylethanolamine, that are chiefly limited to the inner monolayer in normal red blood cells ; (2) a relative
palmitic acid and saturated fatty acid increase and arachidonic acid and unsaturated fatty acid decrease, this resulting in a
lower unsaturation index than controls. Changes in CHS erythrocyte membrane lipids seem to be unrelated to serum lipid
disorders as plasma lipid and apolipoprotein concentrations were apparently in the normal range, with the exception of a
modest hypertriglyceridemia in patients and relatives and a decreased concentration of HDL cholesterol in patients. These
findings indicate that CHS erythrocyte membranes contain an abnormal lipid matrix with which membrane proteins are
defectively associated. The anomalous CHS membrane composition can be explained on the postulated effects of the CHS1/
Lyst gene. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
Chediak^Higashi syndrome (CHS) [1] is a rare ge-
netic disease de¢ned by the presence of giant gran-
ules in all body granule producing cells, particularly
the polymorphonuclear neutrophils, NK cells and
melanocytes. Initial studies at light and electron mi-
croscopic level suggested that these giant granules
arise from the aberrant fusion of ‘lysosomally de-
rived’ organelles one with another. This autosomal
recessive disease has been associated with alterations
such as defective vesicular transport to and from
lysosomes and late endosomes, aberrant compart-
mentalization of lysosomal and granular enzymes,
and inability to secrete the protein content of their
giant granules: defective degranulation [2^5]. The
gene CHS1 [6] or Lyst [7] has recently been mapped
to chromosome 1, 1q42^44, and the gene product
seems to be similar to stathmin, a phosphoprotein
that regulates microtubule polymerization, or to the
yeast vacuolar sorting protein VSP15, involved in
protein tra⁄cking to the yeast vacuole. It has been
suggested that the CHS gene product acts as a lyso-
somal tra⁄cking regulator or plays a role as a com-
ponent of a membrane-associated signal transduction
complex that regulates intracellular protein tra⁄ck-
ing [6]. In the murine model, the beige gene produces
a 400 kDa cytosolic protein that promotes lysosome
¢ssion when overexpressed [8]. Biochemical or mo-
lecular defects caused by the mutant CHS gene are
still not well understood.
In 1966 Windhorst and coworkers [9] described
Chediak^Higashi syndrome as being ‘‘a genetic dis-
ease of the membranes’’. Altered cell membrane and
microtubule functions have been described [10,11].
The best known membrane alteration associated
with CHS is a spontaneous Concanavalin A cap for-
mation [11], which has been related to increased
membrane £uidity and/or defective interactions of
microtubules with cell membranes. Electron spin
resonance studies in CHS leukocytes and erythro-
cytes showed that membranes of both CHS mice
and humans, have abnormally high £uidity [12,13].
A moderate increase in double bonds in fatty acid
components of erythrocyte ghosts in one CHS pa-
tient was reported [13]. An anomalous CHS mem-
brane composition has also been suggested by the
observation of a decrease in some transmembrane
proteins, such as the Na,K-ATPase [14] and the
anionic band 3 [15] in CHS erythrocyte membranes,
and the Ca2 pump in beige mouse lysosome mem-
branes [16]. Other well established CHS cell abnor-
malities related to cell membranes are impaired che-
motaxis and adherence by neutrophils and NK cells
[17^20].
Biological membranes are complex and well-or-
ganized multimolecular assemblies composed of a
wide variety of protein and lipid molecular species.
A general feature of biological membranes is that
lipids are distributed over both lea£ets in a non-ran-
dom fashion. This is especially stressed in the eryth-
rocyte plasma membrane, in which the amino-con-
taining phospholipids, phosphatidylserine (PS) and
phosphatidylethanolamine (PE) are chie£y limited
to the inner monolayer, whereas the outer monolayer
consists predominantly of choline-containing phos-
pholipids, phosphatidylcholine (PC) and sphingo-
myelin (SPM), and glycolipids (i.e., see [21,22]). Since
cholesterol keeps an a⁄nity relationship with sphin-
gomyelin, both lipids seem to co-localize [22,23]. Al-
tered cell membrane function is an accepted feature
of CHS cells, though the biochemical basis for this is
fragmentary. We have therefore examined potential
abnormalities in erythrocyte membrane lipids and in
the fatty acyl species of phospholipids associated
with this syndrome from four Chediak^Higashi syn-
drome patients erythrocytes. Because cholesterol and
phospholipids exchange between erythrocyte mem-
branes and plasma both in vivo and in vitro [24^
26], we have also evaluated the plasma concentration
of total cholesterol, triglycerides, phospholipids, apo-
lipoproteins AI and B100, and the lipid components
of the major lipoprotein classes, very low- (VLDL),
intermediate- (IDL), high- (HDL) and low-density
(LDL) lipoproteins. When compared to controls
our ¢ndings showed that erythrocyte membranes
from CHS patients contain a lipid matrix relatively
enriched with those highly charged choline-contain-
ing phospholipids that, in a normal red blood cell,
are essentially found in the outer monolayer and
with saturated fatty acids, presumably resulting in
changes in membrane asymmetry and the protein/
lipid hydrophobic matching condition. Moreover,
our ¢ndings indicated that membrane proteins seem
to associate defectively with this abnormal lipid ma-
trix.
BBADIS 61976 24-10-00
Y. Chico et al. / Biochimica et Biophysica Acta 1502 (2000) 380^390 381
2. Subjects and methods
2.1. Subjects
Studies were performed in four CHS patients, two
females aged 4 and 23 years, and two males aged 3
and 6 years. All of them were born in Pregonero or
nearby small communities in the State of Ta¤chira,
Venezuela, a cluster of endemic Chediak^Higashi
syndrome [1]. Fifteen direct relatives (parents, broth-
ers and sisters) with ages between 4 and 38 years, and
12 apparently healthy donors from the same area
with ages between 20 and 30 years were included in
the study. The diagnosis of Chediak^Higashi syn-
drome had been established by clinical ¢ndings and
by the presence of large intracytoplasmic azurophilic
granules in polymorphonuclear neutrophils in pe-
ripheral blood smears.
2.2. Blood sampling and serum analysis
Non-fasting blood samples were collected and
transported to the laboratory at 4‡C. The serum
was separated by centrifugation at 800Ug for
15 min, aliquoted and stored at 320‡C as described
by Evans et al. [27] for less than 3 months. An ali-
quot of each serum sample was analyzed for total
cholesterol (TC), triglycerides (TG), phospholipids
(PL), and apolipoproteins AI (apoAI) and B100
(apoB100). TC, TG and PL were determined by
the enzymocolorimetric assays CHOD-PAP (Boehr-
inger Mannheim) and GPO-PAP (Boehringer Mann-
heim), and phospholipase D^colinoxidase-PAP
(Wako Chemicals), respectively. ApoAI and
apoB100 were measured by kinetic nephelometry
with antiserum from Array Protein System (Beckman
Instruments). Precinorm L and Precipath L from
Boehringer Mannheim were used as controls. Serum
was centrifuged at 40 000Ug for 30 min to remove
chylomicrons [28] and then subjected to sequential
£otation ultracentrifugation to isolate very-low-den-
sity lipoproteins (VLDL; d6 1.006 mg/dl), inter-
mediate-density lipoproteins (IDL; 1.006^1.019
mg/dl), low-density lipoproteins (LDL; 1.019^1.063
mg/dl) and high-density lipoproteins (HDL; 1.063^
1.21 mg/dl) [28]. Total cholesterol, triglycerides and
phospholipids of each lipoprotein class were esti-
mated as described above.
2.3. Erythrocyte membrane preparation
Erythrocytes were washed three times with 3 vol-
umes of ice-cold phosphate-bu¡ered saline by centri-
fugation at 1000Ug for 5 min and subsequent re-
moval of the supernatant and the remaining bu¡y
coat. The resulting erythrocyte pellet was suspended
in ice-cold 20 mM phosphate bu¡er (pH 7.4), and
centrifugation was carried out at 17 000Ug for 20 min
at 4‡C. The supernate was aspirated and the tube
rotated at an angle to allow the erythrocyte ghost
pellet to slide away from the underlying smaller pel-
let of leukocytes which was also aspirated. Washes in
20 mM phosphate were repeated until the erythro-
cyte ghost pellet was white. Finally, three washes in
phosphate bu¡ered saline were performed. The
erythrocyte membrane protein content was estimated
by the Peterson method [29] using bovine serum al-
bumin as standard.
2.4. Analysis of erythrocyte membrane lipids and
phospholipid fatty acid composition
Lipids were extracted exhaustively from erythro-
cyte membranes basically by the method of Folch
et al. [30]. One aliquot of lipid extracts was taken
for quantifying free cholesterol (FC) and phospho-
lipid species, and another aliquot for analysis of total
phospholipid fatty acids. The separation and quanti-
¢cation of phospholipid and neutral lipid species was
performed by monodimensional thin layer chroma-
tography and densitometry as described by Ruiz and
Ochoa [31]. Brie£y, plates were developed in a step-
wise fashion in chambers saturated with (i) chloro-
form/methanol/water (65:40:5 v/v/v), (ii) ethyl ace-
tate/2-propanol/ethanol/chloroform/methanol/0.25%
KCl (35:5:20:22:15:9 v/v/v/v/v/v), (iii) toluene/dieth-
yl ether/ethanol (60:40:3 v/v/v), (iv) n-heptane/dieth-
yl ether (94:8 v/v), and (v) pure n-heptane. After
chromatography, lipids were charred and an image
of the plate was acquired and digitalized with an
image analysis system BioImage equipped with a Ko-
dak Videk Megaplus digital camera and a software
Whole Band Sun View from BioImage Corporation
(Ann Arbor, MI). The internal standard, cholesteryl
formate, and standards for FC, PE, PS, PC and SPM
were obtained from Sigma Chemical Co. (St. Louis,
MO).
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Analysis of erythrocyte membrane phospholipid
fatty acids was performed by capillary gas chroma-
tography. Phospholipids were ¢rstly separated from
the other lipids by thin layer chromatography using
n-heptane/diisopropyl ether/acetic acid (70:30:2 v/v/v)
as developing solvent. The fatty acids were meth-
ylated [32] and separated on a 30-m glass capillary
column Omegawax-250 of 0.25 mm internal diameter
and 0.25 Wm wall-coated (Supelco, PA), employing a
Shimadzu gas-chromatograph equipped with a
£ame-ionization detector. Temperatures of column,
detector, and injection port were 195‡C, 250‡C and
250‡C, respectively. Helium was used as the carrier
gas; the inlet pressure was 1.1 kg/cm. The split ratio
was 1:200. Fatty acid methyl esters were identi¢ed by
their retention time according to commercial stan-
dards (NuChek Prep, Elysian, MN). For quantitative
analysis, heptadecanoic acid was added as internal
standard, assuming that the response of the detector
for all methyl-fatty acids was identical. The unsatu-
ration index was calculated by multiplying the num-
ber of double bonds by the percent composition of
the fatty acid in membrane phospholipids and add-
ing up the values.
2.5. Statistical methods
Data are expressed as mean þ S.D. Comparisons
between groups were performed by ANOVA test. P
values equal or less than 0.05 were considered signi¢-
cant.
3. Results
CHS patients showed an enrichment of the lipid
matrix mass relative to protein mass in erythrocyte
membranes, with the group of relatives showing an
intermediate phenotype (Table 1). This was mainly
due to the fact that the amount of protein associated
to CHS erythrocyte membranes averaged a 66% of
the control value. The content of free cholesterol and
phospholipid classes in erythrocyte membranes is dis-
played in Fig. 1. CHS patients had signi¢cant greater
amounts of cholesterol and PL than relatives and
healthy controls, this increase being more marked
in cholesterol and choline-containing phospholipids,
sphingomyelin and phosphatidylcholine, than in ami-
no-containing phospholipids, phosphatidylserine and
phosphatidylethanolamine. Thus, the addition of PC
and SPM content in CHS membranes was 1.87-fold
Table 1
Erythrocyte membrane lipid and protein in Chediak^Higashi syndrome patients, relatives, and controls
Parameter Controls (n = 12) CHS patients (n = 4) Relatives (n = 15)
Lipid/protein (mg/mg) 0.783 þ 0.117 1.696 þ 0.373b;d 1.040 þ 0.153f
Protein (weight%) 56.1 þ 8.4 37.1 þ 8.2a;c 49.1 þ 7.2e
Values are mean þ S.D. Comparisons between Chediak^Higashi syndrome (CHS) patients and controls are indicated by aP9 0.01 and
bP9 0.001, between CHS patients and relatives by cP9 0.05 and dP9 0.001, and between relatives and controls by eP9 0.05 and
f P9 0.001.
Fig. 1. Erythrocyte membrane lipids in Chediak^Higashi syn-
drome patients, relatives and controls.
FC PL SPM PC PE PS Range of values Group
2801 3707 1363 804 934 606 Maximum value CHS
patients
374 889 163 276 201 141 Minimum value
1450 2345 467 667 439 563 Maximum value Relatives
244 472 115 133 104 119 Minimum value
462 892 174 248 295 274 Maximum value Controls
337 512 60 124 165 156 Minimum value
FC, free cholesterol; PC, phosphatidylcholine; SPM, sphingo-
myelin; PS, phosphatidylserine; PE, phosphatidylethanolamine.
The plotted data are the means, and the maximum and mini-
mum values for each lipid class are given in the table. Asterisks
indicate comparisons, which were done using the means þ S.D.,
between Chediak^Higashi syndrome (CHS) patients and con-
trols, *P9 0.05 and **P9 0.001.
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that of relatives and 2.73-fold that of controls,
whereas PE content added to that of PS in CHS
membranes was 1.20-fold that in relatives and 1.59-
fold that estimated in controls. Erythrocytes from
control subjects had a proportion of PC+SPM rela-
tive to PE+PS of 0.76, while the ratio was 0.84 in the
group of relatives and 1.3 in CHS erythrocytes
(P9 0.001). By far, the major increase was in sphin-
gomyelin. CHS membranes contained 3.6 times the
amount of SPM present in controls, which repre-
sented a 70% increase in weight percentage of total
lipids (P9 0.001). On the other hand, phosphatidyl-
serine underwent the lowest increase. In fact, mem-
branes of relatives and patients contained compara-
ble amounts of only this lipid class. The mass of
cholesterol in CHS erythrocyte membranes increased
as markedly as phospholipids containing choline did.
Hence, cholesterol in CHS was 1.97- and 2.67-fold
the level in relatives and controls, respectively. A
consequence of the parallel changes mentioned above
is that neither the cholesterol to total phospholipid
ratio (CHS, 0.42^0.76; relatives, 0.40^0.73; controls,
0.46^0.66) nor the cholesterol to choline-containing
phospholipid ratio (CHS, 1.175 þ 0.085; relatives,
1.112 þ 0.17; controls, 1.198 þ 0.28; means þ S.D.)
varied signi¢cantly between groups.
Table 2 presents the major fatty acids of the eryth-
rocyte membrane phospholipids of Chediak^Higashi
syndrome patients, relatives and controls. Data are
given as mol% of the phospholipid fatty acyl species
listed in the table. The fatty acid pattern in CHS
patients showed three remarkable trends when com-
pared with the control group: (i) in the major com-
ponents there was a marked increase in palmitic acid,
which was accompanied by a decrease in arachidonic
acid, while stearic, oleic and linoleic acids were not
altered substantially; (ii) there was a statistically sig-
ni¢cant increase in saturated fatty acids (SFA) and a
reciprocal decrease in polyunsaturated fatty acids
(PUFA), which resulted in a 60% increase of the
SFA/PUFA ratio and in a 24% decrease of the un-
saturation index; (iii) no signi¢cant di¡erences in
Table 2
Major fatty acids of erythrocyte membrane phospholipids of Chediak^Higashi syndrome patients, relatives, and controls
Fatty acids Controls (n = 12) CHS patients (n = 4) Relatives (n = 15)
13:0 0.71 þ 0.25 4.46 þ 2.71 1.70 þ 1.26
14:0 2.89 þ 0.37 2.26 þ 0.99 1.54 þ 0.89
16:0 (PA) 27.47 þ 2.27 34.32 þ 1.82b;c 29.14 þ 2.67
16:1 n-9 0.84 þ 0.25 0.46 þ 0.62 0.55 þ 0.43
18:0 (SA) 19.84 þ 4.06 19.52 þ 3.03 21.29 þ 3.14
18:1 n-9 (OA) 12.75 þ 1.46 10.85 þ 2.60 12.19 þ 1.37
18:2 n-6 (LA) 10.95 þ 1.47 8.61 þ 4.32 9.80 þ 1.26
20:0 0.32 þ 0.07 0.15 þ 0.11 0.19 þ 0.15
20:1 1.02 þ 0.71 3.52 þ 3.66 1.29 þ 0.81
20:4 n-6 (AA) 11.20 þ 1.41 6.72 þ 4.27a;c 10.20 þ 3.56
22:0 0.73 þ 0.16 0.33 þ 0.25 0.86 þ 0.23
22:4 n-6 2.88 þ 0.48 2.07 þ 0.70 2.82 þ 0.94
22:5 n-3 2.14 þ 0.59 1.05 þ 0.84 1.67 þ 0.61
22:6 n-3 (DHA) 2.18 þ 0.48 2.37 þ 2.44 1.90 þ 0.84
23:0 0.18 þ 0.14 0.10 þ 0.20 0.07 þ 0.16
24:0 1.52 þ 0.40 1.13 þ 0.38 1.53 þ 0.87
24:1 2.37 þ 0.78 2.06 þ 1.13 3.25 þ 3.44
SFA 53.67 þ 3.48 62.28 þ 5.05a 56.32 þ 5.92
MUFA 16.98 þ 1.91 16.89 þ 1.92 17.28 þ 3.55
PUFA 29.35 þ 2.24 20.83 þ 6.32a 26.39 þ 5.47
SFA/PUFA 1.83 þ 0.13 2.99 þ 0.55b;c 2.13 þ 0.37
Unsaturation index 117 89 114
Results are expressed as mol percentage of total phospholipid fatty acids and represent the mean þ S.D. PA, palmitic acid; SA, stearic
acid; OA, oleic acid; LA, linoleic acid; AA, arachidonic acid; DHA, docosahexanoic acid; SFA, total saturated fatty acids; MUFA,
total monounsaturated fatty acids; PUFA, total polyunsaturated fatty acids. Comparisons between Chediak^Higashi syndrome (CHS)
patients and controls are indicated by aP9 0.05 and bP9 0.001, and between CHS patients and relatives by cP9 0.05.
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monounsaturated fatty acids and in those fatty acids
that are in a minority were detected. Total n-6 fatty
acids decreased from 25% to 17.4% of total fatty
acids in CHS as compared to controls, while total
n-3 fatty acids were unchanged. In general, the group
of relatives showed a fatty acid composition similar
to that of controls.
To explore whether there is a relationship between
changes in erythrocyte membrane and plasma lipids,
the plasma concentration of total cholesterol, trigly-
cerides, phospholipids, apoAI, and apoB100, and the
lipid levels in the four major lipoprotein classes were
estimated in controls, relatives and Chediak^Higashi
patients. Table 3 shows the results of these experi-
ments, in which no marked di¡erences between
groups were found. Notwithstanding, it is interesting
to note that patients and relatives had at the time of
the examination a moderate hypertriglyceridemia
and that CHS patients presented signi¢cantly less
HDL cholesterol than controls and relatives. Plasma
concentration of apoAI and the ratio of total choles-
terol to HDL cholesterol were, however, una¡ected
as was the cholesterol LDL/cholesterol HDL ratio.
The rise in phospholipids of plasma and all lipopro-
tein classes measured in CHS patients did not reach
statistical signi¢cance. Taking into account that se-
rum lipid concentrations are a¡ected by several fac-
tors including age, and the ages of patients were 4,
23, 3 and 6, while the ages of relatives ranged from 4
to 38, and controls averaged 25 years, the results of
this part of the study must be interpreted with cau-
tion. What is clear, is that none of the patients had a
lipoprotein-lipid pro¢le that di¡ered substantially
from the values expected according to cross-sectional
studies. Though not shown, hepatic function tests
were done in the three groups, and no alterations
were found in CHS patients.
4. Discussion
The biochemical basis of the Chediak^Higashi syn-
drome is still unknown. This study provides evidence
that CHS erythrocyte membranes contain an abnor-
Table 3
Lipid composition of the serum and lipoprotein classes of Chediak^Higashi syndrome patients, relatives, and controls
Parameter Controls (n = 12) CHS patients (n = 4) Relatives (n = 15)
VLDL TC 22.2 þ 6.7 22.7 þ 5.3 23.9 þ 5.1
TG 64.7 þ 17.6 56.7 þ 13.4 54.6 þ 20.9
PL 59.3 þ 12.7 73.2 þ 8.4 54.6 þ 17.9
IDL TC 15.5 þ 5.6 15.5 þ 4.7 15.0 þ 4.5
TG 13.4 þ 5.3 13.5 þ 4.6 13.3 þ 2.9
PL 17.7 þ 3.5 22.3 þ 2.9 19.2 þ 6.3
LDL TC 112.6 þ 21.1 100.5 þ 21.3 107.1 þ 21.1
TG 20.1 þ 7.1 19.0 þ 1.9 23.1 þ 7.4
PL 80.3 þ 15.2 95.5 þ 14.9 82.3 þ 14.2
HDL TC 53.4 þ 11.4 43.3 þ 1.6b;c 55.5 þ 8.3
TG 19.2 þ 6.7 16.5 þ 4.6 19.1 þ 6.5
PL 74.6 þ 10.2 87.3 þ 8.6 79.4 þ 16.8
Serum TC 197 þ 25 178 þ 37 188 þ 29
TG 120 þ 39 185 þ 44a 177 þ 112d
PL 250 þ 38 292 þ 18 261 þ 47
ApoAI 141 þ 19 131 þ 16 144 þ 14
ApoB100 110 þ 21 94 þ 15 90 þ 26
ApoB100/apoAI 0.78 þ 0.12 0.72 þ 0.11 0.63 þ 0.14
TC-serum/TC-HDL 3.69 þ 0.63 4.11 þ 0.40 3.39 þ 0.51
TC-LDL/TC-HDL 2.11 þ 0.42 2.32 þ 0.31 1.93 þ 0.29
Lipid and apoprotein concentrations are expressed as mg/dl. TC, total cholesterol ; TG, triglycerides; PL, phospholipids; VLDL, very-
low-density lipoprotein; IDL, intermediate-density lipoprotein; LDL, low-density lipoprotein; HDL, high-density lipoprotein; ApoAI,
apolipoprotein AI; ApoB100, apolipoprotein B100. Values are means þ S.D. Comparisons between Chediak^Higashi syndrome (CHS)
patients and controls are indicated by aP9 0.05 and bP9 0.001, between CHS patients and relatives by cP9 0.001, and between rela-
tives and controls by dP9 0.001.
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mal lipid matrix with which membrane proteins are
defectively associated. We show that: (i) the trans-
bilayer lipid distribution is probably impaired in
CHS membranes because of a relatively higher en-
richment in cholesterol and those highly-charged
choline-containing phospholipids that, in a normal
red blood cell, localize in the external hemilea£et;
(ii) the degree of saturation in the phospholipid fatty
acids was higher in CHS erythrocytes than in con-
trols; (iii) the changes in CHS erythrocyte membrane
lipids seem to be unrelated to serum lipid disorders.
Chediak^Higashi syndrome is an autosomal reces-
sive disorder that causes formation of giant organ-
elles in most body cells, the most conspicuous being
neutrophil lysosomes, melanosomes and cytolytic
granules. The mechanism through which these giant
granules are formed is unknown. It was originally
proposed that the neutrophil giant inclusions arise
from fusion of small lysosomes in bone marrow pre-
cursor cells [33] or from the abnormal fusion of en-
larged primary granules with normal secondary gran-
ules [34,35]. Fusion of individual granules with each
other and with phagocytic vacuoles occurs normally
during bacterial phagocytosis, but in unaltered white
cell union of lysosomes is extremely rare. The possi-
bility that the CHS defect lies in a protein that is
involved in vesicle fusion in all cell types, but crucial
for the secretion of the lysosomal compartment in
certain cell types belonging to the hemopoietic line-
age has recently been suggested [18]. An understand-
ing of membrane molecular architecture in CHS cells
may help not only to understand the cell e¡ect of the
deleterious gene, but also to elucidate how vesicle
fusion/¢ssion is regulated. It is known that the eryth-
rocyte membrane is asymmetrically distributed, with
the amino-containing phospholipids residing almost
exclusively in the inner lea£et, whereas the outer
monolayer consists predominantly of choline-con-
taining phospholipids, as well as glycolipids and cho-
lesterol (i.e., see [21,22]). CHS membranes were
found to be enriched with cholesterol, PC, and
SPM with relation to aminophospholipids. In order
to maintain membrane stability, this might result in
transbilayer equilibration of part of the highly
charged choline-containing lipids that in a normal
erythrocyte localizes in the external hemilea£et, and
in CHS membranes would occupy the inner half of
the bilayer. It is of particular interest that increased
transbilayer migration of phospholipids has been re-
ported to occur at fusion sites during vesicle budding
[22,36,37]. The functional importance of lipid asym-
metry is not clear but it is certainly not accidental, as
the asymmetric distribution of phospholipid is main-
tained by an aminophospholipid translocase, a
Mg2-dependent ATPase, that transports PS and
PE but not PC from outer to inner plasma mem-
brane lea£et (for a review, see [22]). Lipid asymmetry
has been suggested to be related to maintenance of a
fusion competent surface for endocytosis and organ-
elle fusion and to prevention of exposure of phos-
phatidylserine at the outer surface of a cell, which is
supposed to be a signal of senescence [38]. Indeed,
abnormal asymmetry of the head-group distribution
has been reported for aged red cells, sickle cells, ma-
laria infected red cells, to name only some (i.e., see
[38^40]). The physiological consequences of a lipid
asymmetry abnormality are unknown, but it would
probably be expressed as altered lipid^lipid interac-
tions ^ altered fusion/¢ssion ^ and defective associa-
tion with membrane proteins, and both phenotypic
features are found in Chediak^Higashi syndrome pa-
tients. With respect to proteins, ample evidence has
accumulated to support the general view that a hy-
drophobic mismatch with the lipids is expected to
have consequences on their conformation and/or ag-
gregation state, and therefore, on their activity (for a
recent review, see [41]). This would explain many of
the cellular and biochemical disturbances observed in
CHS cells such as the concanavalin-A spontaneous
capping, reduced number of Na,K-ATPase pumps
and band 3 protein [14,15] and would add support to
the suggestion that a generalized membrane abnor-
mality may be associated with the molecular defect
responsible for this syndrome [9,13].
Di¡erent phenotypes generally characterize a spe-
ci¢c disorder. In this regard, it is to remark that CHS
patients as well as their relatives exhibited a variable
degree of erythrocyte membrane lipid alterations.
The most striking changes, which are shown in Fig.
1, corresponded to a 4-year-old CHS girl, and her
both parents and two brothers had also rather severe
lipid alterations. A third sibling showed, however,
lipid values within the control range. An atypical
CHS patient because of her age, 23 years old (most
CHS patients perish at an earlier age), but with all
phenotypic manifestations of this syndrome, showed
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what could be called an ‘intermediate type’ of mem-
brane composition. All her relatives, including her
only 14-year-old brother, had normal erythrocyte
membrane lipids. Moderate membrane modi¢cations
were recorded in both parents of the other two 3-
and 6-year-old CHS cases studied, whose lipid alter-
ations were not severe. Only one of them had one
sibling, who presented a normal erythrocyte lipid
pro¢le. This variability in CHS erythrocyte mem-
brane lipid composition agrees with results from
studies of receptor membrane mobility in CHS poly-
morphonuclear neutrophils [11,15], and seems to in-
dicate that some CHS patients may be less severely
a¡ected by the mutated gene than others, as sup-
ported by clinical ¢ndings in patients from this
CHS cluster [42]. It has been suggested that epistatic
factors might play some role in clinical presentation
variability [43]. The fact that the cases here studied
derived from a genetic cluster strengthen this postu-
lation. Previous reports in the literature have also
indicated the existence of alterations in the known
heterozygous subjects for the Chediak^Higashi gene
similar to those observed in the homozygous condi-
tion; i.e., abnormal lysosomal enzymatic content,
chemotactic activity of neutrophils or Epstein^Barr
virus-speci¢c serological pattern [44]. These have
been considered as indicative of partial expression
of the CHS gene. The herein reported di¡erences in
lipid composition among relatives can be attributed
to a similar mechanism. The limited number of fam-
ilies and of descendants made di⁄cult to ¢rmly es-
tablish whether the membrane lipid alterations were
only present in CHS gene carriers.
The main lipid modulators of membrane £uidity
and order variation are considered to be the choles-
terol/phospholipid ratio and the fatty acid composi-
tion of phospholipids. This has been postulated to be
particularly true for membranes, such as that of the
erythrocyte, rich in PC and SPM which contain no-
ticeable amounts of saturated fatty acids, especially
palmitic acid, and in which cholesterol may have a
£uidizing role [23]. Increased phospholipid levels
were reported by Ingraham et al. [13] when studying
£uidity properties of erythrocyte membranes in one
4-year-old CHS patient. The authors observed that
CHS erythrocyte membranes tend to have higher
£uidity, an increased proportion of unsaturated fatty
acids and higher phospholipids with respect to the
content of cholesterol than normal [13]. Here we ob-
served that the ratios of cholesterol to total phospho-
lipids or to choline-containing phospholipids were
comparable in the four patients and controls, and
that CHS erythrocyte membranes had an increased
proportion of palmitic acid and saturated fatty acids,
and a decreased proportion of arachidonic acid and
polyunsaturated fatty acids, and lower unsaturation
index. Whether the reciprocal variations in PUFA
and SFA, the possible unphysiologic reduction of
n-6 fatty acids, and the parallel increase in phospho-
lipid and cholesterol, do or do not have an e¡ect on
CHS membrane physico-chemical parameters is un-
certain. If the SFA/PUFA ratio is used as a £uidity
modulator, our results indicate that CHS patients
have erythrocyte membranes less £uid than controls,
which clashes with the generally accepted thesis that
greater £uidity is exhibited by CHS erythrocytes [13].
This may be interpreted to mean that £uidity
markers are not useful predictive tools in those mem-
branes showing profound disturbances in lipid orga-
nization. Direct physicochemical studies are needed
to conclude on a general trend towards molecular
motion in CHS membranes. Let us ¢nally say that
it is not surprising to ¢nd result di¡erences when
very few cases are studied and the parameter under
study is multivariant. For example, it is well known
that membrane fatty acid composition is profoundly
in£uenced by diet, and neither the CHS patient
studied by Ingraham et al. [13] nor the four CHS
patients studied here were on a controlled diet at
the time of examination.
Because cholesterol and phospholipids exchange
between erythrocyte membranes and plasma both
in vivo and in vitro [24^26], potential e¡ects of plas-
ma lipoproteins on the erythrocyte membrane lipids
might occur. However, lipid and apolipoprotein
composition of plasma and lipoprotein classes of
Chediak^Higashi syndrome patients were found to
be similar to relatives and controls, with the excep-
tion of a moderate hypertriglyceridemia in CHS pa-
tients and relatives and decreased plasma concentra-
tion of HDL cholesterol in patients. It seems,
therefore, unlikely that the high content of phospho-
lipid and cholesterol in CHS erythrocyte membranes
derives from lipoprotein exchange. On the contrary,
it might be well speculated that there is an abnormal
cholesterol e¥ux from cell membranes to the accept-
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ing apoAI-containing HDL due to a cell plasma
membrane disfunction. As far as we are aware, there
is only one case report in which serum lipid studies
were performed [45]. It was a 16-year-old girl who
had at the time of examination hypertriglyceridemia,
normal total phosphorous, an increased PC fraction
and a reduced SPM fraction, and low serum choles-
terol and K1-lipoproteins. A similar abnormality in
the distribution of the PC/SPM ratio was found in
the serum of both parents and in the three surviving
siblings, and the mother and brother had hypertri-
glyceridemia. The ¢ndings led the authors to suggest
that lipid disturbances are likely to be dissociated
from the Chediak^Higashi syndrome and related to
another genetic disorder. Indeed, the same authors
recorded an unpublished case of an 18-year-old
male subject with leukocyte abnormality but with
values of triglycerides, phospholipids and K1-lipopro-
teins within the normal range. Apart from this, high
concentrations of apoB100 confer increased risk for
vascular disease, and lower apoB100 concentrations
bring bene¢ts, as does high HDL. The total number
of the clearly atherogenic apoB100-containing lipo-
protein particles (VLDL, IDL and LDL) make up
more than 90% of the total number of apo B par-
ticles present in plasma [46]. In this work, neither
plasma apoAI nor apoB100 concentrations in CHS
patients di¡ered from controls. All these ¢ndings re-
inforce the idea that erythrocyte membrane and lipo-
protein lipid disfunctions are coexisting defects but
are not directly related. In any case, as mentioned
above, caution must be taken when interpreting the
¢ndings in this part of the study as di¡erences in age,
probably diet, lifestyle and other factors in£uencing
plasma lipids certainly occurred in controls, relatives
and CHS patients.
Even though the CHS gene has recently been
mapped to chromosome 1, 1q42^44, the gene prod-
uct still remains elusive. Several hypothesis regarding
its nature and function have been, however, ad-
vanced: relationship with proteins associated with
vesicle transport; homology to stathmin, a phospho-
protein that regulates the polymerization of micro-
tubules; and its role as a component of a membrane-
associated signal transduction complex that regulates
intracellular protein tra⁄cking. Perinuclear accumu-
lation of tyrosinase TRP-1 and granulophysin, and
excessive translocation of tyrosinase-containing
vesicles have been described in cultured melanocytes
[5] and interpreted as being due to an abnormal traf-
¢cking of some cellular proteins. Similarly, the re-
ported di¡erences in the cellular cytoplasmic distri-
bution of some cytoskeleton proteins, platelet
membrane glycoprotein abnormalities, as well as a
decrease of the Ca2 pump in beige mouse lysosomes
membranes [16] and of some transmembrane pro-
teins in Chediak^Higashi erythrocyte membranes
such as the anionic band 3 protein [15], and have
also been recently reinterpreted as being due to a
defective protein tra⁄cking [15]. Our observations,
though compatible with the postulated role of the
putative CHS gene product in the regulation of intra-
cellular vesicle transport and/or protein tra⁄cking,
indicate that the abnormality in erythrocyte mem-
brane lipid composition is a true consequence of
the mutated CHS gene. This supports and extends
the idea that defects in the overall functioning of
cell membrane-associated components may be re-
lated with the molecular defect responsible for this
syndrome.
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